Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Ahead of print

Issues

THC and CBD concentrations in blood, oral fluid and urine following a single and repeated administration of “light cannabis”

Roberta Pacifici / Simona Pichini / Manuela Pellegrini / Maria Concetta Rotolo / Raffaele Giorgetti / Adriano Tagliabracci / Francesco Paolo Busardò / Marilyn A. Huestis
  • Lambert Center for the Study of Medicinal Cannabis and Hemp, Institute of Emerging Health Professions, Thomas Jefferson University, Philadelphia, PA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2019-04-08 | DOI: https://doi.org/10.1515/cclm-2019-0119

Abstract

Background

“Light cannabis” is a product legally sold in Europe with Δ9-tetrahydrocannabinol (THC) concentration lower than 0.2% and variable cannabidiol (CBD) content. We studied THC and CBD excretion profiles in blood, oral fluid (OF) and urine after smoking one or four light cannabis cigarettes.

Methods

Blood, OF and urine samples were obtained from six healthy light cannabis consumers after smoking one 1 g cigarette containing 0.16% THC and 5.8% CBD and from six others after smoking four 1 g cigarettes within 4 h. Sample collection began 0.5 and 4.5 h after smoking one or four cigarettes, respectively. Cannabinoid concentrations were quantified by gas chromatography-mass spectrometry (GC-MS).

Results

At the first collection, the highest THC and CBD concentrations occurred in blood (THC 7.0–10.8 ng/mL; CBD 30.2–56.1 ng/mL) and OF (THC 5.1–15.5 ng/mL; CBD 14.2–28.1 ng/mL); similar results occurred 0.5 h after the last of four cigarettes in blood (THC 14.1–18.2 ng/mL, and CBD 25.6–45.4 ng/mL) and OF (THC 11.2–24.3 ng/mL; CBD 14.4–37.0 ng/mL). The mean OF to blood ratio ranged from 0.6 to 1.2 after one and 0.6 to 1.9 after four light cannabis cigarettes. THC/CBD ratios in blood and OF were never greater than 2. Urinary 11-nor-9-carboxy-THC concentrations peaked 8 h after one and four cigarettes.

Conclusions

OF was a valuable alternative to blood in monitoring consumption of light cannabis. Blood and OF THC/CBD concentration ratios, never exceeded 2, possibly providing a useful biomarker to identify light cannabis vs illegal higher THC cannabis use, where THC/CBD ratios are generally greater than 10.

Keywords: Δ9-tetrahydrocannabinol (THC); blood; light cannabis; oral fluid; urine; variable cannabidiol (CBD)

References

  • 1.

    Regulation (EU) no 1307/2013 of the European parliament and of the council at https://eurlex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2013:347:0608:0670:EN:PDF.

  • 2.

    European regulation 1155, 2017 at https://eur-lex.europa.eu/eli/reg_del/2017/1155/oj.

  • 3.

    Legal cannabis at https://www.puntog-shop.com/cannabis-legale-dam-ice.html.

  • 4.

    The Swiss cannabis, 2017 at https://www.theguardian.com/science/2017/nov/24/the-swiss-cannabisfarm-aiming-to-supply-legal-weed-across-europe.

  • 5.

    Pacifici R, Pichini S, Pellegrini M, Tittarelli R, Pantano F, Mannocchi G, et al. Determination of cannabinoids in OF and urine of “light cannabis” consumers: a pilot study. Clin Chem Lab Med 2018;57:238–43.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 6.

    Newmeyer MN, Swortwood MJ, Barnes AJ, Abulseoud OA, Scheidweiler KB, Huestis MA. Free and glucuronide whole blood cannabinoids’ pharmacokinetics after controlled smoked, vaporized, and oral cannabis administration in frequent and occasional cannabis users: identification of recent cannabis intake. Clin Chem 2016;62:1579–92.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 7.

    Desrosiers NA, Himes SK, Scheidweiler KB, Concheiro-Guisan M, Gorelick DA, Huestis MA. Phase I and II cannabinoid disposition in blood and plasma of occasional and frequent smokers following controlled smoked cannabis. Clin Chem 2014;60:631–43.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 8.

    Lee D, Vandrey R, Milman G, Bergamaschi M, Mendu DR, Murray JA, et al. OF/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal Bioanal Chem 2013;405:7269–79.CrossrefWeb of ScienceGoogle Scholar

  • 9.

    Peters FT, Wissenbach DK, Busardo FP, Marchei E, Pichini S. Method development in forensic toxicology. Curr Pharm Des 2017;23:5455–67.PubMedGoogle Scholar

  • 10.

    Wille SM, Coucke W, De Baere T, Peters FT. Update of standard practices for new method validation in forensic toxicology. Curr Pharm Des 2017;23:5442–54.PubMedGoogle Scholar

  • 11.

    Bergamaschi MM, Barnes AJ, Queiroz RH, Hurd Y, Huestis MA. Impact of enzyme and alkaline hydrolysis on CBD concentration in urine. Anal Bioananal Chem 2013;405:4679–89.CrossrefGoogle Scholar

  • 12.

    Verstraete AG. Detection times of drugs of abuse in blood, urine, and OF. Ther Drug Monit 2004;26:200–5.CrossrefPubMedGoogle Scholar

  • 13.

    Wille SM, Ramírez-Fernandez Mdel M, Samyn N, De Boeck G. Conventional and alternative matrices for driving under the influence of cannabis: recent progress and remaining challenges. Bioanalysis 2010;2:791–806.CrossrefWeb of SciencePubMedGoogle Scholar

  • 14.

    Marsot A, Audebert C, Attolini L, Lacarelle B, Micallef J, Blin O. Comparison of cannabinoid concentrations in plasma, OF and urine in occasional cannabis smokers after smoking cannabis cigarette. J Pharm Pharm Sci 2016;19:411–22.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 15.

    Lee D, Milman G, Schwope DM, Barnes AJ, Gorelick DA, Huestis MA. Cannabinoid stability in authentic OF after controlled cannabis smoking. Clin Chem 2012;58:1101–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 16.

    Lee D, Vandrey R, Milman G, Bergamaschi M, Mendu DR, Murray JA, et al. OF/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal Bioanal Chem 2013;405:7269–79.CrossrefWeb of ScienceGoogle Scholar

  • 17.

    Newmeyer MN, Desrosiers NA, Lee D, Mendu DR, Barnes AJ, Gorelick DA, et al. Cannabinoid disposition in OF after controlled cannabis smoking in frequent and occasional smokers. Drug Test Anal 2014;6:1002–10.Web of SciencePubMedCrossrefGoogle Scholar

  • 18.

    Toennes SW, Ramaekers JG, Theunissen EL, Moeller MR, Kauert GF. Pharmacokinetic properties of delta9-tetrahydrocannabinol in OF of occasional and chronic users. J Anal Toxicol 2010;34:216–21.PubMedCrossrefGoogle Scholar

  • 19.

    Fabritius M, Chtioui H, Battistella G, Annoni JM, Dao K, Favrat B, et al. Comparison of cannabinoid concentrations in OF and whole blood between occasional and regular cannabis smokers prior to and after smoking a cannabis joint. Anal Bioanal Chem 2013;405:9791–803.CrossrefWeb of SciencePubMedGoogle Scholar

  • 20.

    Swortwood MJ, Newmeyer MN, Andersson M, Abulseoud OA, Scheidweiler KB, Huestis MA. Cannabinoid disposition in OF after controlled smoked, vaporized, and oral cannabis administration. Drug Test Anal 2017;9:905–15.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 21.

    Samyn N, Verstraete A, van Haeren C, Kintz P. Analysis of drugs of abuse in saliva. Forensic Sci Rev 1999;11:1–19.PubMedGoogle Scholar

  • 22.

    Kidwell D, Holland J, Athanaselis S. Testing for drugs of abuse in saliva and sweat. J Chromatogr B 1998;713:111–35.CrossrefGoogle Scholar

  • 23.

    Navarro M, Pichini S, Farré M, Ortuño J, Roset PN, Segura J, et al. Usefulness of saliva for measurement of 3,4-methylenedioxymethamphetamine and its metabolites: correlation with plasma drug concentrations and effect of salivary pH. Clin Chem 2001;47:1788–95.PubMedGoogle Scholar

  • 24.

    Solowij N, Broyd SJ, van Hell HH, Hazekamp A. A protocol for the delivery of cannabidiol (CBD) and combined CBD and Δ9-tetrahydrocannabinol (THC) by vaporisation. BMC Pharmacol Toxicol 2014;15:58.CrossrefWeb of SciencePubMedGoogle Scholar

  • 25.

    Gentili S, Solimini R, Tittarelli R, Mannocchi G, Busardò FP. A study on the reliability of an on-site OF drug test in a recreational context. J Anal Methods Chem 2016;2016: 1234581.Web of ScienceGoogle Scholar

  • 26.

    Desrosiers NA, Lee D, Schwope DM, Milman G, Barnes AJ, Gorelick DA, et al. On-site test for cannabinoids in OF. Clin Chem 2012;58:1418–25.CrossrefWeb of SciencePubMedGoogle Scholar

  • 27.

    Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017;2:139–54.CrossrefPubMedGoogle Scholar

  • 28.

    Bergamaschi MM, Queiroz RH, Zuardi AW, Crippa JA. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6:237–49.CrossrefPubMedGoogle Scholar

  • 29.

    Babson KA, Sottile J, Morabito D. Cannabis, cannabinoids, and sleep: a review of the literature. Curr Psychiatry Rep 2017;19:23.Web of SciencePubMedCrossrefGoogle Scholar

  • 30.

    Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol 2018;9:2009.CrossrefWeb of ScienceGoogle Scholar

About the article

Corresponding author: Simona Pichini, PhD, National Centre on Addiction and Doping Istituto Superiore di Sanità, V.le Regina Elena 299, 00161 Rome, Italy, Phone: +39 06 49906544, Fax: +39 06 49902016


Received: 2019-02-01

Accepted: 2019-03-12

Published Online: 2019-04-08


Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: Presidency of the Ministers Council, Department of Antidrug Policy.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organisation(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.


Citation Information: Clinical Chemistry and Laboratory Medicine (CCLM), 20190119, ISSN (Online) 1437-4331, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/cclm-2019-0119.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in